Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share.

The question is whether those gains justify a valuation well above industry levels. WST’s growth drivers remain attractive, but the premium multiple leaves less room for operational missteps.

WST's HVP Growth Supports the Bull Case

HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organically. Biologics, GLP-1 elastomers and customer upgrades tied to Annex 1 requirements supported the increase.

West Pharmaceutical Services, Inc. Revenue (Quarterly)

West Pharmaceutical Services, Inc. revenue-quarterly | West Pharmaceutical Services, Inc. Quote

Management expects Annex 1 and broader HVP conversion to add about 200 basis points to 2026 revenue growth. West has just under 800 related projects in hand, up 50% from a year earlier.

Eli Lilly and Company LLY is advancing retatrutide in late-stage obesity and diabetes development, underscoring continued innovation in metabolic therapies. Novo Nordisk A/S NVO remains focused on obesity and diabetes, including newer Wegovy formats, reinforcing the breadth of the GLP-1 market.

West's Margins Improve as Mix Shifts Higher

Second-quarter gross margin expanded 200 basis points year over year to 37.7%. Adjusted operating margin increased 230 basis points to 22.6%, helped by favorable HVP mix, pricing and operating leverage.

Management now expects more than 200 basis points of full-year operating-margin expansion compared with 2025. The richer product mix is helping offset inflationary pressure from oil and other commodities.

WST's Valuation Leaves Less Room for Error

WST trades at 37.1X forward 12-month earnings, versus 18.0X for its Zacks sub-industry and 20.7X for the S&P 500. That is a sizable relative premium.

The multiple is below WST’s five-year median of 39.1X, so the stock is not expensive relative to its own recent history. Still, investors are paying substantially more than peer and market benchmarks for the company’s expected growth.

Image Source: Zacks Investment Research

West Faces Execution and Cost Risks

West Vantage grew just 0.8% organically in the second quarter. Cyber-related production downtime reduced the segment’s gross margin, and management expects the third quarter to mark the trough before improvement later in the year.

Standard Products grew only 0.7% organically. Commodity inflation and the July 1 transfer of SmartDose 3.5mL manufacturing and supply rights add further variables as West works through portfolio and operating changes.

WST's Balance Sheet Adds Flexibility

West ended June with $435.8 million in cash and cash equivalents against $202.9 million of total debt. That balance sheet provides capacity to support HVP investments while continuing shareholder returns.

The company repurchased 1.8 million shares for $454.3 million in the first half of 2026 under its $1 billion authorization. First-half capital spending declined to $85.9 million from $146.5 million a year earlier, while the quarterly dividend remains 22 cents per share.

Wrapping Up

The operating case is improving, but valuation and execution risk make the entry decision less straightforward. HVP growth, margin expansion and balance sheet flexibility support the long-term thesis, while the premium multiple argues for price discipline.

Currently, West carries a Zacks Rank #3 (Hold). Likewise, Eli Lilly and Novo Nordisk also carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research